NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Question 1

What is Gilead Sciences' stock symbol?

Answer

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Question 2

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Answer

Gilead Sciences announced a quarterly dividend on Wednesday, July 25th. Shareholders of record on Friday, September 14th will be given a dividend of $0.57 per share on Thursday, September 27th. This represents a $2.28 annualized dividend and a yield of 3.02%. The ex-dividend date is Thursday, September 13th. View Gilead Sciences' Dividend History.

Question 3

How were Gilead Sciences' earnings last quarter?

Answer

Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Wednesday, July, 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks' consensus estimate of $1.56 by $0.35. The biopharmaceutical company earned $5.65 billion during the quarter, compared to the consensus estimate of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business's quarterly revenue was down 20.9% compared to the same quarter last year. During the same period last year, the business posted $2.56 EPS. View Gilead Sciences' Earnings History.

Question 4

When is Gilead Sciences' next earnings date?

Answer

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Gilead Sciences.

Question 5

What price target have analysts set for GILD?

Answer

22 Wall Street analysts have issued twelve-month price targets for Gilead Sciences' shares. Their predictions range from $72.00 to $105.00. On average, they expect Gilead Sciences' share price to reach $88.2650 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

Question 6

What is the consensus analysts' recommendation for Gilead Sciences?

Answer

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 10 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

Question 7

What are Wall Street analysts saying about Gilead Sciences stock?

Answer

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe which should boost sales further. The initial uptake of Yescarta is encouraging in the United States and the CHMP gave a positive opinion on the same. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio. Shares have outperformed the industry in the year so far. Estimates for Q2 are up by two cents in the last thirty days ahead of the results (scheduled for July 25). However, Gilead’s HCV franchise is under pressure due to competitive and pricing pressure." (7/18/2018)
2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)

Question 8

Who are some of Gilead Sciences' key competitors?

Answer

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Acceleron Pharma (XLRN), argenx (ARGX), Aerie Pharmaceuticals (AERI) and Repligen (RGEN).

Question 9

Who are Gilead Sciences' key executives?

Answer

Gilead Sciences' management team includes the folowing people:

Dr. John F. Milligan, CEO, Pres & Director (Age 57)
Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
Mr. Kevin B. Young, Advisory (Age 60)
Dr. John G. McHutchison, Exec. VP of Research, Clinical R&D and Chief Scientific Officer
Sung Lee, VP of Investor Relations

Question 10

Has Gilead Sciences been receiving favorable news coverage?

Answer

Headlines about GILD stock have trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gilead Sciences earned a news impact score of 0.18 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Gilead Sciences.

Question 11

Who are Gilead Sciences' major shareholders?

Answer

Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.12%), Bank of New York Mellon Corp (2.38%), FMR LLC (1.51%), Parnassus Investments CA (1.50%), Northern Trust Corp (1.30%) and Sanders Capital LLC (0.81%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Question 12

Which institutional investors are selling Gilead Sciences stock?

Answer

GILD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FMR LLC, Renaissance Technologies LLC, Bank of Nova Scotia, Caisse DE Depot ET Placement DU Quebec, American Century Companies Inc., ANTIPODES PARTNERS Ltd and Oppenheimer & Co. Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Question 13

Which institutional investors are buying Gilead Sciences stock?

Answer

GILD stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Natixis, Los Angeles Capital Management & Equity Research Inc., Sanders Capital LLC, Mainstay Capital Management LLC ADV, Unigestion Holding SA, Diamond Hill Capital Management Inc. and Royal London Asset Management Ltd.. View Insider Buying and Selling for Gilead Sciences.

Question 14

How do I buy shares of Gilead Sciences?

Answer

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 15

What is Gilead Sciences' stock price today?

Answer

One share of GILD stock can currently be purchased for approximately $75.51.

Question 16

How big of a company is Gilead Sciences?

Answer

Gilead Sciences has a market capitalization of $95.77 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

Question 17

How can I contact Gilead Sciences?

Answer

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		1,872 (Vote Outperform)
Underperform Votes:		786 (Vote Underperform)
Total Votes:		2,658

NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Receive GILD News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions